Induction effects of ritonavir: Implications for drug interactions

Annals of Pharmacotherapy

Volumn 42, Issue 7-8, 2008, Pages 1048-1059

  Foisy, Michelle M ^a,c   Yakiwchuk, Erin M ^a   Hughes, Christine A ^a,b  

^a Capital Health Edmonton   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ROYAL ALEXANDRA HOSPITAL   (Canada)

Author keywords

Cytochrome P450 enzyme system; Drug interactions; Enzyme induction; P glycoprotein; Protease inhibitors; Ritonavir; Uridine diphosphate glucuronosyltransferase enzymes

Indexed keywords

ACENOCOUMAROL; ALPRAZOLAM; AMFEBUTAMONE; ATAZANAVIR; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DARUNAVIR; EFAVIRENZ; GLYCOPROTEIN P; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MEFLOQUINE; METHADONE; NELFINAVIR; NEVIRAPINE; OLANZAPINE; PETHIDINE; PHENYTOIN; RITONAVIR; SAQUINAVIR; SERTRALINE; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

AREA UNDER THE CURVE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG METABOLISM; ENZYME INDUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

ARYL HYDROCARBON HYDROXYLASES; DRUG INTERACTIONS; ENZYME ACTIVATORS; ENZYME INDUCTION; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; ISOENZYMES; RITONAVIR;

EID: 48249104628     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K615     Document Type: Review

References (98)

1. Product monograph. Norvir (ritonavir). Chicago, IL: Abbott Laboratories, May 2007.
2. Product monograph. Kaletra (lopinavir/ritonavir). North Chicago, IL: Abbott Laboratories, October 2005.
3. Lee CGL, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37:3594-601. DOI 10.1021/bi972709x
4. Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997;41:898-905.
5. Phillips EJ, Rachlis AR, Ito S. Digoxin toxicity and ritonavir: a drug interaction mediated through P-glycoprotein? AIDS 2003;17:1577-8. DOI 10.1097/00002030-200307040-00026
6. Ding R, Tayrouz Y, Riedel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004;76:73-84.
7. Penzak SR, Shen JM, Alfaro RM, et al. Ritonavir decreases the nonrenal clearance of digoxin and in healthy volunteers with known MDR1 genotypes. Ther Drug Monit 2004;26:322-30. DOI 10.1097/00007691-200406000-00018
8. Vishnuvardhan D, von Moltke LL, Richert C, Greenblatt DJ. Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS 2003;17:1092-4. DOI 10.1097/00002030-200305020-00023
9. Drewe J, Gutman H, Flicker G, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999;57:1147-52. DOI 10.1016/S0006-2952(99)00026-X
10. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999;13:1623-7. DOI 10.1097/00002030-199909100-00004
11. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001;29:754-60.
12. Perloff MD, von Moltke LL, Marchand JE, Greenblatt DJ. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci 2001;90:1829-37. DOI 10.1002/jps.1133
13. van Heeswijk RPG, Bourbeau M, Campbell P, et al. Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 2006;46:758-67. DOI 10.1177/0091270006288733
14. Guengerich FP. Cytochrome P450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17. DOI 10.1146/annurev. pharmtox.39.1.1
15. Huisman MT, Smit JW, Schinkel AH. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000;14:237-42. DOI 10.1097/00002030-200002180-00005
16. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 2005;78:664-74. DOI 10.1016/j.clpt.2005.09.001
17. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and 1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60.
18. Hogeland GW, Swindells S, McNabb JC, Kashuba ADM, Yee GC, Lindley CM. Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 2007;81:69-75. DOI 10.1038/sj.clpt.6100027
19. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46:111-6. DOI 10.1046/j.1365-2125.1998.00749.x
20. Hsu A, Granneman GR, Bertz RJ. Ritonavir clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35:275-91.
21. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-96. DOI 10.1056/ NEJM200103293441307
22. Product monograph. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., February 2007.
23. Vourvahis M, Kashuba ADM. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 2007;27:888-909. DOI 10.1592/phco.27.6.888
24. De Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003;42:223-82.
25. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007; 35:1853-9. DOI 10.1124/dmd.107.016089
26. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 1999;19:293-6. DOI 10.1097/00004714-199908000-00001
27. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 2000;67:335-41. DOI 10.1067/mcp.2000.105757
28. Frye R, Bertz R, Grannerman GR, et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam (abstract A59). Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28-October 1, 1997.
29. Khaliq Y, Gallicano K, Tisdale C, Carignan G, Cooper C, McCarthy A. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers. Br J Clin Pharmacol 2001;51:591-600. DOI 10.1046/j.1365-2125.2001. 01393.x
30. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58:737-47. DOI 10.1007/PL00000897
31. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
32. Hsu A, Granneman GR, Witt G. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline (abstract Mo.B.1200). Presented at: 11th International Conference on AIDS, Vancouver, BC, July 7-12, 1996.
33. Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW. Influence of ritonavir on olanzapine pharmacokinetics. J Clin Psychopharmacol 2002;22:366-70. DOI 10.1097/01.jcp.0000024575.36017.5d
34. Kalra BS. Cytochrome P450 enzyme isoforms and their therapeutic implications; an update. Indian J Med Sci 2007;61:102-16.
35. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. Ottawa, Ontario: Canadian Pharmacists Association, 2004.
36. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005;106:97-132. DOI 10.1016/j. pharmthera.2004.10.013
37. De Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol 2003;6:57-72. DOI 10.1017/S1461145703003249
38. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part I. Psychosomatics 2003;44:167-71. DOI 10.1176/appi.psy.44.2.167
39. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II. Psychosomatics 2003;44:515-20. DOI 10.1176/appi.psy.44.6.515
40. Kharasch ED, Mitchelle D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother Epub 19 Feb 2008 2008;52:1663-9. DOI 10.1128/AAC.01600-07
41. Piscitelli SC, Kress DR, Bertz RJ, Pau A, Davey R. The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy 2002;20:549-53. DOI 10.1592/phco.20.6.549.35162
42. Product monograph. Sustiva (efavirenz). Montreal, QC: Bristol-Myers Squibb Canada, January 2007.
43. Boyd MA, Aarnoutse RE, Ruxrungtham K, Stek M, van Heeswijk RPG, Lange JMA. Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. J Acquir Immune Defic Syndr 2003;34:134-9. DOI 10.1097/00126334-200310010-00003
44. Product monograph. Viramune (nevirapine). Burlington, ON: Boehringer Ingelheim Canada, July 2007.
45. Sekar VJ, De Pauw M, Marien K, et al. Pharmacokinetic interaction between TMC 114/r and efavirenz in healthy volunteers. Antiviral Therapy 2007;12:509-14.
46. Roszko PJ, Curry K, Brazina B, et al. Standard doses of efavirenz (EFV), zidovudine (ZDV), tenofovir (TDF), and didanosine (ddI) may be given with tipranavir/ritonavir (TPV/r) (abstract 865). Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, France, July 13-16, 2003.
47. Sekar V, De Paepe E, De Marez T, et al. Pharmacokinetic interaction between darunavir (TMC 114), a new protease inhibitor, and the selective serotonin reuptake inhibitors (SSRIs), paroxetine and sertraline (abstract P295). Presented at: 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 12-16, 2006.
48. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998;32:1299-1302. DOI 10.1345/aph.17456
49. Gatti G, Alessandrini A, Cemera M, Di Baggio A, Bassetti M, Rizzo F. Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS 1998;12:825-6.
50. Hughes CA, Freitas A, Miedzinski LI. Interaction between lopinavir/ritonavir and warfarin. CMAJ 2007;177:357-9. DOI 10.1503/cmaj.061284
51. Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P450 induction. J Acquir Immune Defic Syndr 2004;36:1034-40. DOI 10.1097/00126334- 200408150-00006
52. Bonora S, Calcagno A, Fontana S, et al. Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. Clin Infect Dis 2007;45:1654-5. DOI 10.1086/523722
53. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P450 2B6 and 2C19. Chirality 2004; 16:36-44. DOI 10.1002/chir.10303
54. Bertz R, Hsu A, Lam W, et al. Pharmacokinetic interactions between Kaletra and non-HIV drugs (abstract 438). Presented at: 5th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, October 22-26, 2000.
55. Clarke S, Mulcahy F, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 2002;34:1143-5. DOI 10.1086/339541
56. Hsu A, Granneman GR, Carothers L, et al. Ritonavir does not increase methadone exposure in healthy volunteers (abstract 342). Presented at: 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1-5, 1998.
57. Gerber JG, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr 2001;27: 153-60.
58. Sekar V, El Malt M, De Paepe E, et al. Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and methadone (abstract P294). Presented at: 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 12-16, 2006.
59. Liu P, Foster G, Labadie R, Allison MJ, Sharma A. Pharmacokinetic interaction between voriconazole and ritonavir at steady state in healthy subjects (abstract). Clin Pharmacol Ther 2005;77:P40.
60. Product monograph. VFEND* (voriconazole). Kirkland, QC: Pfizer Canada Inc., August 2004.
61. Product monograph. Prezista (darunavir). Raritan, NJ: Tibotec Therapeutics, Division of Ortho Biotech Products, February 2008.
62. Sheehan NL, Brouillette M-J, Delisle M-S, Allan J. Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. Ann Pharmacother 2006;40:147-50. Epub 29 Nov 2008. DOI 10.1345/aph.1G418
63. DiCenzo R, Peterson D, Cruttenden K, et al. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2004;48:4328-31.
64. Tseng A, Fletcher D. Interaction between ritonavir and levothyroxine (correspondence). AIDS 1998;12:2235-6.
65. Touzot M, Le Beller C, Touzot F, Louet ALL, Piketty C. Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient (correspondence). AIDS 2006;20:1210-1. DOI 10.1097/01.aids.0000226969. 96880.3c
66. van der Lee MJ, Dawood L, ter Hofstede HJM, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 2006;80:159-68. DOI 10.1016/j.clpt.2006.04.014
67. Bertz RJ, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard JM. Effect of ritonavir on the pharmacokinetics of trimethoprim/sulfamethoxazole (abstract Mo.B.1197). Presented at: 11th International Conference on AIDS, Vancouver, BC, July 7-12, 1996.
68. Cato A 3rd, Qian J, Hsu A, Levy B, Leonard J, Granneman R. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998;42: 1788-93.
69. Product monograph. Intelence (etravirine). Raritan, NJ: Tibotec, Inc., January 2008.
70. Baede P, Piscitelli S, Graham N, Van't Klooster G. Drug interactions with TMC125, a potent next generation NNRTI (abstract A-1827). Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 27-30, 2002.
71. Scholler M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir boosted with ritonavir in healthy subjects (abstract 583). Presented at: 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8, 2006.
72. Wenning LA, Hanley H, Stone J, et al. Effect of tipranavir + ritonavir (tpv + Rtv) on pharmacokinetics of MK-0518 (abstract A-374). Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006.
73. Product monograph. Isentress (raltegravir). Whitehouse Station, NJ: Merck & Co., Inc., October 2007.
74. Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ. Apparent mechanism-based inhibition of CYP3A in-vitro by lopinavir. J Pharm Pharmacol 2003;55:381-6. DOI 10.1211/002235702739
75. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001;29:100-2.
76. Ramirez J, Innocenti F, Schuetz EG, et al. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 2004;32:930-6.
77. Hesse LM, Greenblatt DJ, von Moltke LL, Court MH. Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. J Clin Pharmacol 2006;46: 567-76. DOI 10.1177/0091270006286981
78. Wall TL, Schoedel K, Ring HZ, Luczak SE, Katsuyoshi DM, Tyndale RF. Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research. Nicotine Tob Res 2007;9(suppl 3):459-74. DOI 10.1080/14622200701587045
79. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005;44:111-45. DOI 10.2165/00003088-200544020-00001
80. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005;33:262-70. DOI 10.1124/dmd.104.002428
81. Tagahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001;40:587-603. DOI 10.2165/00003088-200140080-00003
82. Llibre JM, Romeu J, López E, Sirera G. Severe interaction between ritonavir and acenocoumarol. Ann Pharmacother 2002;36:621-3. DOI 10.1345/aph.19361
83. Newshan G, Tsang P. Ritonavir and warfarin interaction (correspondence). AIDS 1999;13:1788. DOI 10.1097/00002030-199909100-00028
84. Goto S, Seo T, Murata T, et al. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Ther Drug Monit 2007;29:118-21. DOI 10.1097/FTD.0b013e318030def0
85. Luthi B, Huttner A, Speck RF, Mueller NJ. Methadone-induced torsade de pointes after stopping lopinavir-ritonavir. Eur J Clin Microbiol Infect Dis 2007;26:367-9. DOI 10.1007/s10096-007-0293-5
86. McCance-Katz EF, Rainey PM, Friedlund G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003;37:476-82. DOI 10.1086/376907
87. Stevens RC, Rapaport S, Maroldo-Connelly L, Patterson JB, Bertz R. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir-ritonavir. J Acquir Immune Defic Syndr 2003;33:650-1. DOI 10.1097/00126334-200308150-00016
88. Shelton MJ, Cloen D, Di Francesco R, et al. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J Clin Pharmacol 2004;44:293-304. DOI 10.1177/0091270003262956
89. Jamois C, Riek M, Patel A, Smith P, Morrison R, Schmitt C. Effect of boosted saquinavir on the pharmacokinetics and pharmacodynamics of racemic methadone in opiate-dependent patients on stable methadone maintenance therapy (abstract P293). Presented at: 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 12-16, 2006.
90. Geletko SM, Erickson AD. Decreased methadone effect after ritonavir administration. Pharmacotherapy 2000;20:93-4. DOI 10.1592/phco.20.1.93.34654
91. Product monograph. Agenerase capsules (amprenavir). Research Triangle Park, NC: GlaxoSmithKline, May 2007.
92. Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005;19:1635-41. DOI 10.1097/01.aids. 0000183628.20041.f2
93. Mikus G, Schowel V, Drzewinska M, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80:126-35. DOI 10.1016/j.clpt.2006.04.004
94. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43(suppl1):S28-39. DOI 10.1086/504492
95. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyl transferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin conjugation. Drug Metab Dispos 2005;33:1729-39. DOI 10.1124/dmd.105.005447
96. Smith CM, Faucette SR, Wang H, LeCluyse EL. Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers. J Biochem Mol Toxicol 2005;19:96-108. DOI 10.1002/jbt.20058
97. Burger DM, Huisman A, van Ewijk N, et al. The effect of atazanavir and atazanavir/ritonavir on UGT 1A4 using lamotrigine as a phenotypic probe (abstract 566). Presented at: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007.
98. Burger DM. US National Institutes of Health, Clinical Trials. Drug interaction study between atovaquone and antiretroviral agents in HIV-1 infected patients (NCT00421473). http://clinicaltrials.gov/show/NCT00421473 (accessed 2008 Jan 15).